drugset

drugset / Trial / NCT02628028

A Study of LY3337641 in Rheumatoid Arthritis

NCT02628028 ↗

Phase 2 Terminated 286 enrolled Eli Lilly and Company

RandomizedParallel-groupTriple-blindTreatment

Summary

The main purpose of this study is to evaluate the safety and effectiveness of LY3337641 in adults with rheumatoid arthritis (RA).

Timeline

Start: 2016-08-22
Primary completion: 2018-04-25
Completion: 2018-08-15

Publications

Genovese MC, Spindler A, Sagawa A, Park W, Dudek A, Kivitz A, Chao J, Chan LSM, Witcher J, Barchuk W, Nirula A. Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study. J Rheumatol. 2021 Jul;48(7):969-976. doi: 10.3899/jrheum.200893. Epub 2020 Dec 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Poseltinib	Unknown	5 mg	Oral
Subject	Poseltinib	Unknown	10 mg	Oral
Subject	Poseltinib	Unknown	30 mg	Oral

Indications